1
|
Solarczyk K, Waligórska A, Uznańska K, Prucsi Z, Wójcikowska O, Matuszyk E, Bartyńska M, Kitlińska A, Bober A, Sierpowski F, Białecka M, Jarosz M, Szczygiel M, Koman S, Korpanty K, Beben L, Bandzarewicz L, Stachura P, Kordon-Kiszala M. Abstract 6108: Novel functional dSTRIDE-HR assays to report on the status of homologous recombination repair in cancer cells. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-6108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Since the early days of the synthetic lethality concept in DNA Damage Response the status of homologous recombination (HR) repair in cancer cells have been the focus of attention of researchers and clinicians. While different approaches exist, such as the RAD51 immunofluorescence (IF) or HRD genomic assays, functional biomarkers that can assess HR proficiency are missing. We report here the development, optimization and validation of two complementary, HR-specific functional assays. The assays, which are based on the STRIDE platform technology, detect double-strand DNA breaks localized in close proximity to RPA or RAD51 proteins. The optimization phase of assay development was performed in U2OS cells. First, repeatability (intra-run variation) and reproducibility (inter-run variation) of the assays were measured in untreated cells. Then, a series of technical negative controls was performed which have shown that the number of false-positive readouts is below 10% of the total number of signals. Finally, treatment of cells with compounds known to induce double-strand DNA breaks (etoposide and cisplatin) resulted in statistically significant increase in the number of detected dSTRIDE-RAD51 and dSTRIDE-RPA foci when compared to untreated controls. The assays were further validated in NCI-H661 (BRCA2 wild-type) and NCI-H169 (BRCA2 KO) cell line pair. The cells were treated with two concentrations of etoposide and the readouts from dSTRIDE, detecting the total pool of DSBs and dSTRIDE-HR assays were compared. In NCI-H661 cells, treatment with etoposide resulted in an increase in the number of double-strand breaks detected by dSTRIDE and as expected, more DSBs were formed after treatment with the higher concentration. dSTRIDE-HR assays confirmed that approximately 15% and 10% of these DSBs contain RPA and RAD51 proteins, respectively. In NCI-H169 cells etoposide produced a stronger reaction with even more DSBs detected by dSTRIDE, but importantly, no increase in the number of dSTRIDE-RAD51 foci was observed. dSTRIDE-RPA foci increased after treatment hinting that this step of HR remains unperturbed. Interestingly, the number of dSTRIDE-RAD51 foci in untreated cells was comparable between the two cell lines. In conclusion, we show here that two newly developed dSTRIDE-HR assays are well validated and can be successfully applied to report on the status of homologous recombination repair in different cell models.
Citation Format: Kamil Solarczyk, Agnieszka Waligórska, Karolina Uznańska, Zsombor Prucsi, Olga Wójcikowska, Ewelina Matuszyk, Magdalena Bartyńska, Agata Kitlińska, Aleksandra Bober, Franek Sierpowski, Maja Białecka, Monika Jarosz, Malgorzata Szczygiel, Szymon Koman, Karolina Korpanty, Lukasz Beben, Lukasz Bandzarewicz, Przemyslaw Stachura, Magdalena Kordon-Kiszala. Novel functional dSTRIDE-HR assays to report on the status of homologous recombination repair in cancer cells. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6108.
Collapse
|
2
|
Boutard N, Białas A, Sabiniarz A, Guzik P, Banaszak K, Biela A, Bień M, Buda A, Bugaj B, Cieluch E, Cierpich A, Dudek Ł, Eggenweiler H, Fogt J, Gaik M, Gondela A, Jakubiec K, Jurzak M, Kitlińska A, Kowalczyk P, Kujawa M, Kwiecińska K, Leś M, Lindemann R, Maciuszek M, Mikulski M, Niedziejko P, Obara A, Pawlik H, Rzymski T, Sieprawska‐Lupa M, Sowińska M, Szeremeta‐Spisak J, Stachowicz A, Tomczyk MM, Wiklik K, Włoszczak Ł, Ziemiańska S, Zarębski A, Brzózka K, Nowak M, Fabritius C. Discovery and Structure–Activity Relationships of
N
‐Aryl 6‐Aminoquinoxalines as Potent PFKFB3 Kinase Inhibitors. ChemMedChem 2018; 14:169-181. [DOI: 10.1002/cmdc.201800569] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Revised: 10/13/2018] [Indexed: 01/09/2023]
Affiliation(s)
| | | | | | - Paweł Guzik
- Selvita S.A. Bobrzyńskiego 14 30-348 Kraków Poland
| | | | - Artur Biela
- Selvita S.A. Bobrzyńskiego 14 30-348 Kraków Poland
| | - Marcin Bień
- Selvita S.A. Bobrzyńskiego 14 30-348 Kraków Poland
- Current address: Almac Group 20 Seagoe Industrial Estate Craigavon BT63 5QD UK
| | - Anna Buda
- Selvita S.A. Bobrzyńskiego 14 30-348 Kraków Poland
| | | | | | - Anna Cierpich
- Selvita S.A. Bobrzyńskiego 14 30-348 Kraków Poland
- Current address: Grupa Azoty S.A. Kwiatkowskiego 8 33-100 Tarnów Poland
| | - Łukasz Dudek
- Selvita S.A. Bobrzyńskiego 14 30-348 Kraków Poland
| | | | - Joanna Fogt
- Selvita S.A. Bobrzyńskiego 14 30-348 Kraków Poland
| | - Monika Gaik
- Selvita S.A. Bobrzyńskiego 14 30-348 Kraków Poland
- Current address: Max Planck Research Group at the Małopolska Centre of Biotechnology Jagiellonian University Krakow Poland
| | | | | | - Mirek Jurzak
- Discovery Pharmacology, Merck Biopharma Merck KGaA Frankfurter Straße 250 64293 Darmstadt Germany
| | | | | | | | - Katarzyna Kwiecińska
- Selvita S.A. Bobrzyńskiego 14 30-348 Kraków Poland
- Current address: Captor Therapeutics Duńska 11 54-427 Wrocław Poland
| | - Marcin Leś
- Selvita S.A. Bobrzyńskiego 14 30-348 Kraków Poland
| | - Ralph Lindemann
- Translational Innovation Platform Oncology, Merck Biopharma Merck KGaA Frankfurter Straße 250 64293 Darmstadt Germany
| | - Monika Maciuszek
- Selvita S.A. Bobrzyńskiego 14 30-348 Kraków Poland
- Current address: LifeArc Accelerator Building, Open Innovation Campus Stevenage SG1 2FX UK
| | | | | | - Alicja Obara
- Selvita S.A. Bobrzyńskiego 14 30-348 Kraków Poland
| | | | | | | | | | | | | | - Mateusz M. Tomczyk
- Selvita S.A. Bobrzyńskiego 14 30-348 Kraków Poland
- Current address: Katedra Chemii Organicznej Bioorganicznej I Biotechnologii Ul. B. Krzywoustego 4, P., 18/N1 44-100 Gliwice Poland
| | | | - Łukasz Włoszczak
- Selvita S.A. Bobrzyńskiego 14 30-348 Kraków Poland
- Current address: Grupa Adamed Pieńków 149 05-152 Czosnów Poland
| | | | | | | | | | | |
Collapse
|
3
|
Rzymski T, Mikula M, Żyłkiewicz E, Dreas A, Wiklik K, Gołas A, Wójcik K, Masiejczyk M, Wróbel A, Dolata I, Kitlińska A, Statkiewicz M, Kuklinska U, Goryca K, Sapała Ł, Grochowska A, Cabaj A, Szajewska-Skuta M, Gabor-Worwa E, Kucwaj K, Białas A, Radzimierski A, Combik M, Woyciechowski J, Mikulski M, Windak R, Ostrowski J, Brzózka K. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains. Oncotarget 2018; 8:33779-33795. [PMID: 28422713 PMCID: PMC5464911 DOI: 10.18632/oncotarget.16810] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2016] [Accepted: 03/09/2017] [Indexed: 11/25/2022] Open
Abstract
Inhibition of oncogenic transcriptional programs is a promising therapeutic strategy. A substituted tricyclic benzimidazole, SEL120-34A, is a novel inhibitor of Cyclin-dependent kinase 8 (CDK8), which regulates transcription by associating with the Mediator complex. X-ray crystallography has shown SEL120-34A to be a type I inhibitor forming halogen bonds with the protein's hinge region and hydrophobic complementarities within its front pocket. SEL120-34A inhibits phosphorylation of STAT1 S727 and STAT5 S726 in cancer cells in vitro. Consistently, regulation of STATs- and NUP98-HOXA9- dependent transcription has been observed as a dominant mechanism of action in vivo. Treatment with the compound resulted in a differential efficacy on AML cells with elevated STAT5 S726 levels and stem cell characteristics. In contrast, resistant cells were negative for activated STAT5 and revealed lineage commitment. In vivo efficacy in xenotransplanted AML models correlated with significant repression of STAT5 S726. Favorable pharmacokinetics, confirmed safety and in vivo efficacy provide a rationale for the further clinical development of SEL120-34A as a personalized therapeutic approach in AML.
Collapse
Affiliation(s)
| | - Michał Mikula
- Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland
| | | | | | | | | | | | | | - Anna Wróbel
- R&D Department, Selvita S.A., Kraków, Poland
| | | | | | | | - Urszula Kuklinska
- Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland
| | - Krzysztof Goryca
- Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland
| | | | - Aleksandra Grochowska
- Department of Gastroenterology, Hepatology and Clinical Oncology, Medical Center for Postgraduate Education, Warsaw, Poland
| | - Aleksandra Cabaj
- Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland.,Laboratory of Bioinformatics, Nencki Institute of Experimental Biology, Warsaw, Poland
| | | | | | | | | | | | | | | | | | | | - Jerzy Ostrowski
- Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland.,Department of Gastroenterology, Hepatology and Clinical Oncology, Medical Center for Postgraduate Education, Warsaw, Poland
| | | |
Collapse
|
4
|
Rzymski T, Mikula M, Szajewska-Skuta M, Zyłkiewicz E, Sapała Ł, Dolata I, Kitlińska A, Goryca K, Grochowska A, Cabaj A, Dreas A, Kucwaj K, Białas A, Radzimierski A, Gołas A, Windak R, Ostrowski J, Brzózka K. Abstract 1663: Selective CDK8 inhibitor SEL120-34A alters expression of interferon-related DNA damage resistance signature genes in colorectal cancer. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-1663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
CDK8 (cyclin-dependent kinase 8) is a kinase component of a multi - protein Mediator complex, involved in transcription control. Several studies indicated that high overexpression and activity of CDK8 could be a driver of malignant progression in colorectal cancer (CRC). Herewith we present molecular insights into mechanism of action of SEL120-34A - a selective small molecule inhibitor of CDK8 kinase. Biochemical and binding studies indicated that SEL120-34A selectively binds and inhibits enzymatic activity of CDK8 in the low nM range. Recently CDK8 has been described as a regulator of STAT1 activity in NK cells where by phosphorylating STAT1 serine 727 (Ser727) influences a possible immunoescape mechanism in various cancers. Consistently, SEL120-34A and other recently reported selective CDK8 inhibitors could repress phosphorylation of STAT1 at a Ser727 at low nM concentrations in cancer cells without any significant changes on tyrosine sites directly regulated by JAK kinases. SEL120-34A inhibited expression of several STAT1 dependent genes in CRC cell lines, stimulated by various cytokines and growth factors. These results were further corroborated with specific CDK8 siRNA knockdown experiments and chromatin immunoprecipitation studies showing CDK8 occupancy on promoters of SEL120-34A regulated genes. In order to better characterize in vivo mechanism of action, mice bearing HCT116 and Colo205 xenograft tumors were treated with SEL120-34A and gene expression changes were measured with microarrays in excised tumors. In animals treated with the CDK8 inhibitor a dose dependent repression of STAT1 Ser727 was observed. The functional analyses of significantly (adj. p. value < 0.05) altered genes with Gene Ontology revealed that those with reduced expression belong to interferon I pathway and type I interferon-mediated signaling pathway terms. This subset of STAT regulated genes was further characterized as an interferon-related DNA damage resistance signature (IRDS) - a prosurvival pathway which correlated strongly with resistance to radiation and chemotherapy in various tumors. Consistently, SEL120-34A has shown very potent cytotoxic synergy with standard of care drugs in CRC, particularly in cells stimulated with interferons. Taken together, for the first time we have shown that selective CDK8 inhibitors are potent regulators of STAT related - IRDS signaling pathway in vitro and in vivo. In addition to previously reported stand-alone efficacy of CDK8 inhibitors in vivo, we provide also a combination treatment rationale for CRC.
Citation Format: Tomasz Rzymski, Michał Mikula, Małgorzata Szajewska-Skuta, Eliza Zyłkiewicz, Łukasz Sapała, Izabela Dolata, Agata Kitlińska, Krzysztof Goryca, Aleksandra Grochowska, Aleksandra Cabaj, Agnieszka Dreas, Katarzyna Kucwaj, Artur Białas, Adam Radzimierski, Aniela Gołas, Renata Windak, Jerzy Ostrowski, Krzysztof Brzózka. Selective CDK8 inhibitor SEL120-34A alters expression of interferon-related DNA damage resistance signature genes in colorectal cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1663. doi:10.1158/1538-7445.AM2015-1663
Collapse
Affiliation(s)
| | - Michał Mikula
- 2Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland
| | | | | | | | | | | | - Krzysztof Goryca
- 2Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland
| | - Aleksandra Grochowska
- 2Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland
| | - Aleksandra Cabaj
- 2Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland
| | | | | | | | | | | | | | - Jerzy Ostrowski
- 2Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland
| | | |
Collapse
|
5
|
Szyprowska S, Choma A, Glowacka M, Gronek E, Kitlińska A, Rola M. Occurrence of lipopolysaccharide alterations among Tn5 mutants of Rhizobium leguminosarum bv. trifolii strain 24.1 with altered colony morphology. Acta Biochim Pol 1999; 45:1001-9. [PMID: 10397346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
Transposon mutants of Rhizobium leguminosarum bv. trifolii 24.1 showing less glossy or smaller colonies were screened for properties usually associated with lipopolysaccharide (LPS) defects in R. leguminosarum, i.e. motility, growth rate, tendency to agglutination in liquid media and symbiotic efficiency. Neither any of the above mutants nor the earlier isolated 24.12 strain, defective in LPS, showed all these properties changed simultaneously. According to PAGE/sodium deoxycholate analysis the mutant 24.12 was the only one producing defective lipopolysaccharide. GC-MS analysis revealed in this mutant qualitative changes in composition of its LPS in comparison with LPS isolated from the parent strain. Other Tn5 mutants produced LPSs similar in composition, however the proportion between LPS I and LPS II differed from that in the parent strain.
Collapse
Affiliation(s)
- S Szyprowska
- Department of General Microbiology, M. Curie-Skłodowska University, Lublin, Poland
| | | | | | | | | | | |
Collapse
|
6
|
Szyprowska S, Choma A, Glowacka M, Gronek E, Kitlińska A, Rola M. Occurrence of lipopolysaccharide alterations among Tn5 mutants of Rhizobium leguminosarum bv. trifolii strain 24.1 with altered colony morphology. Acta Biochim Pol 1998. [DOI: 10.18388/abp.1998_4357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Transposon mutants of Rhizobium leguminosarum bv. trifolii 24.1 showing less glossy or smaller colonies were screened for properties usually associated with lipopolysaccharide (LPS) defects in R. leguminosarum, i.e. motility, growth rate, tendency to agglutination in liquid media and symbiotic efficiency. Neither any of the above mutants nor the earlier isolated 24.12 strain, defective in LPS, showed all these properties changed simultaneously. According to PAGE/sodium deoxycholate analysis the mutant 24.12 was the only one producing defective lipopolysaccharide. GC-MS analysis revealed in this mutant qualitative changes in composition of its LPS in comparison with LPS isolated from the parent strain. Other Tn5 mutants produced LPSs similar in composition, however the proportion between LPS I and LPS II differed from that in the parent strain.
Collapse
|